Vanin-1 inactivation antagonizes the development of adrenocortical neoplasia in Sf-1 transgenic mice

Perle Latre de Late1, Abeer El Wakil, Marielle Jarjat

  • 1Institut de Pharmacologie Moléculaire et Cellulaire CNRS (P.L.D.L., A.E.W., M.J., E.L.) Valbonne 06560, France; Associated International Laboratory for the Study of the ALterations of Gene Expression in Childhood Cancers CNRS (P.L.D.L., A.E.W., M.J., E.L.), Valbonne 06560, France; Université de Nice-Sophia Antipolis (P.L.D.L., A.E.W., M.J., E.L.), Valbonne 06560, France; Department of Pathology (R.R.K.), Erasmus MC-University Medical Center, Rotterdam 3015, The Netherlands; Department of Molecular and Integrative Physiology (L.L.H.), University of Kansas Medical Center, Kansas City, Kansas 66160; Centre d'Immunologie de Marseille-Luminy (P.N.), Aix-Marseille University, UM2, Marseille, France; Institut National de la Santé et de la Recherche Médicale (P.N.), U1104, Marseille, France; and Centre National de la Recherche Scientifique (P.N.), UMR7280, Marseille, France.

Endocrinology
|April 10, 2014
PubMed

Insights

Steroidogenic factor 1 (SF-1) overexpression drives adrenal cancer. Targeting Vanin-1 (Vnn1), an SF-1 target gene, reduces tumor severity by modulating oxidative stress and glutathione production.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Steroidogenic factor 1 (SF-1) overexpression is linked to adrenocortical tumor formation and poor prognosis in adrenal cancer.
  • SF-1 plays a crucial role in adrenal cortex development and function.

Purpose of the Study:

  • To identify novel modulators of SF-1's tumorigenic effects in the adrenal cortex.
  • To investigate the role of Vanin-1 (Vnn1) in SF-1-induced adrenocortical neoplasia.

Main Methods:

  • Utilized SF-1 transgenic mice to study adrenocortical tumor formation.
  • Generated SF-1 transgenic mice lacking the Vnn1 gene (SF-1/Vnn1 null).
  • Administered cysteamine to SF-1/Vnn1 null mice to assess reversibility of effects.

Main Results:

  • SF-1 transgenic mice developed age-dependent adrenocortical neoplastic lesions.
  • Genetic ablation of Vnn1 significantly reduced the severity of these lesions.
  • Cysteamine treatment reversed the protective effect of Vnn1 ablation, indicating Vnn1's role.

Conclusions:

  • Vanin-1 (Vnn1), a SF-1 target gene, acts as a novel modulator of SF-1-induced adrenocortical tumorigenesis.
  • Vnn1's pantetheinase activity, influencing cysteamine levels and glutathione production, is critical in this process.
  • Altering redox and detoxification pathways is key in the pathogenesis of SF-1-driven adrenocortical neoplasia.